Neurocrine biosciences announces classic congenital adrenal hyperplasia supplement published today in the journal of clinical endocrinology & metabolism

San diego , jan. 21, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced publication of a classic congenital adrenal hyperplasia (cah)-focused supplement in the journal of clinical endocrinology & metabolism (jcem), sponsored by the company. the supplement, titled "challenges and opportunities in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency throughout the lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic cah.
NBIX Ratings Summary
NBIX Quant Ranking